BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents. Sequential treatment with immunotherapy may produce an ...

Shaji Kumar, MD, Mayo Clinic, focuses on the selection, outcomes, and real-world impact of BCMA-targeted bispecific antibodies for multiple myeloma. He emphasizes the factors influencing choice of ...

Emerging immunotherapy treatments for multiple myeloma target B-cell maturation antigen (BCMA), a protein found on the surface of cancer cells. Multiple myeloma is a blood cancer that develops when ...

B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies. This is an ASCO Meeting Abstract from the 2025 ASCO ...

A retrospective analysis presented at the American Society of Hematology annual meeting looked at multiple myeloma patients' responses to teclistamab (Tecvayli), including among those previously ...

After European regulators jumped on a global-first approval for Johnson & Johnson’s BCMA-targeted bispecific drug Tecvayli, the U.S. FDA has doled out its own blessing for the novel therapy. But the U ...

Sometimes a drug target is just a drug target. But B cell maturation antigen (BCMA) is not just one of the hottest targets for multiple myeloma; it is also a testing ground for therapeutic platforms ...

Please provide your email address to receive an email when new articles are posted on . The FDA cleared an investigational new drug application for P-BCMA-ALLO1, a chimeric antigen receptor T-cell ...

STONY BROOK, N.Y.--(BUSINESS WIRE)--iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for autoimmune disorders and cancer, today announced the publication ...

Please provide your email address to receive an email when new articles are posted on . Clinicians who treat patients with chimeric antigen receptor T cells have become adept at identifying and ...